The science behind the certainty
A single, noninvasive dd-cfDNA blood test for heart transplant monitoring. Early insight into active rejection risk may change everything.
The current surveillance landscape has limitations and the management of heart transplant recipients is complex and challenging
Precision optimized for enhanced performance
Reduce the number of surveillance biopsies by using Prospera as your first-line surveillance test
Patients First, Partners Always
Natera’s suite of solutions allows for streamlined process integration for your center
Find out more about Prospera for heart transplant recipients
1Natera Inc. Natera validation data: manuscript submitted. Data on file.
2Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2018 (per published article);8(1):19 doi:10.3390/jcm8010019
3Altug Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation. 2019;103(12):2657-2665. doi:10.1097/TP.0000000000002665
4Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902 doi:10.1016/j. jmoldx.2016.07.0038.
5U.S. Department of Health & Human Services: Health Resources and Services Administration. Scientific Registry of Transplant Recipients (SRTR): Organ Procurement and Transplantation Network (OPTN)/SRTR 2019 Annual Data Report: Heart. Available at: https://srtr.transplant.hrsa.gov/annual_reports/2019/Heart. aspx#HR_tx_adult_inc_AR_age_b64. Accessed June 1, 2021.
6Toyoda Y, Toyoda Y. Heart-lung transplantation: adult indications and outcomes. J Thorac Dis. 2014;6(8):1138-1142. doi:10.3978/j.issn.2072-1439.2014.06.01